Aadi Bioscience (AADI) Stock Price, News & Analysis

Company Overview

Aadi Bioscience, Inc. is a clinical-stage biopharmaceutical company focused on developing precision medicines for genomically defined cancers. Headquartered in Redwood City, California, Aadi Bioscience was founded in 2012 and went public in 2019 on the Nasdaq Stock Market under the ticker AADI. The company’s research strategy centers on identifying molecular drivers of tumor growth and designing small-molecule inhibitors that target these pathways.

The company’s lead product candidate, fimepinostat (CUDC-907), is a novel dual inhibitor of histone deacetylase (HDAC) and phosphatidylinositol 3-kinase (PI3K). Fimepinostat is currently being evaluated in multiple Phase 1/2 clinical trials in patients with relapsed or refractory non-Hodgkin lymphomas, pediatric high-risk neuroblastoma and other genomically defined malignancies. Aadi Bioscience has established collaborations with leading academic centers in the United States and Europe to advance the clinical development of fimepinostat and explore combination regimens with other targeted therapies.

In addition to its lead program, Aadi Bioscience is advancing a discovery pipeline aimed at identifying novel targets in rare and aggressive cancers with unmet medical needs. The company’s integrated approach combines biomarker-driven patient selection with translational research capabilities to streamline clinical development and enhance the probability of success. Aadi’s team includes seasoned executives and oncology researchers, led by President and Chief Executive Officer Stephen J. Waintraub, who bring extensive experience in drug development, regulatory affairs and commercialization in the oncology sector.

Key Stats

• Today's Range: $1.86 to $2.00
• 50-Day Range: $1.60 to $2.01
• 52-Week Range: $1.21 to $3.81
• Volume: 175,247 shs
• Average Volume: 261,100 shs
• Market Capitalization: $47.91 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: N/A

AADI Stock Analysis - Frequently Asked Questions

How have AADI shares performed this year?

Aadi Bioscience's stock was trading at $3.15 at the start of the year. Since then, AADI shares have decreased by 38.4% and is now trading at $1.94.

How were Aadi Bioscience's earnings last quarter?

Aadi Bioscience, Inc. (NASDAQ:AADI) released its earnings results on Tuesday, March, 18th. The company reported ($0.67) EPS for the quarter, missing the consensus estimate of ($0.30) by $0.37. The business earned $7.24 million during the quarter, compared to analysts' expectations of $7.45 million. Aadi Bioscience had a negative net margin of 246.06% and a negative trailing twelve-month return on equity of 71.87%.
Read the conference call transcript.

When did Aadi Bioscience's stock split?

Shares of Aadi Bioscience reverse split before market open on Friday, August 27th 2021.The 1-15 reverse split was announced on Thursday, August 26th 2021. The number of shares owned by shareholders was adjusted after the closing bell on Wednesday, August 25th 2021. An investor that had 100 shares of stock prior to the reverse split would have 7 shares after the split.

How do I buy shares of Aadi Bioscience?

Shares of AADI stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of Aadi Bioscience own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Aadi Bioscience investors own include Meta Platforms (META), Advanced Micro Devices (AMD), Tesla (TSLA), JPMorgan Chase & Co. (JPM), Moderna (MRNA), NVIDIA (NVDA) and Alphabet (GOOG).

Company Calendar

• Last Earnings: 3/18/2025
• Today: 10/04/2025
• Next Earnings (Estimated): 11/04/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: Pharmaceutical preparations
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NASDAQ:AADI
• CIK: 1422142
• Web: aadibio.com
• Phone: (424) 473-8055
• Fax: N/A
• Employees: 40
• Year Founded: 2011

Profitability

• EPS (Trailing Twelve Months): ($2.35)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$65.76 million
• Net Margins: -246.06%
• Pretax Margin: -246.06%
• Return on Equity: -71.87%
• Return on Assets: -57.28%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 4.89
• Quick Ratio: 4.54

Sales & Book Value

• Annual Sales: $25.07 million
• Price / Sales: 1.91
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $4.29 per share
• Price / Book: 0.45

Miscellaneous

• Outstanding Shares: 24,697,000
• Free Float: 15,485,000
• Market Cap: $47.91 million
• Optionable: Optionable
• Beta: 0.68